New drug data makes this French biotech stock a buy, says Jefferies

§ 01 Executive Snapshot

• What: Abivax's stock is upgraded to buy by Jefferies following positive data on its ulcerative colitis treatment.
• Who: Jefferies analyst Faisal Khurshid, Abivax management, and patients involved in the drug trials.
• Why it matters: The upgrade reflects renewed confidence in Abivax's treatment efficacy and management's ability to address investor concerns, potentially increasing shareholder value.

§ 02 Key Developments

• Jefferies upgraded Abivax from hold to buy and raised the price target from $108 to $158, indicating an 18% upside from Tuesday's close.
• New data revealed malignancies in patients taking obefazimod were consistent with normal levels for ulcerative colitis patients.
• Over one-third of initially non-responsive patients achieved remission after approximately 10 months of treatment.
• Abivax shares surged 39% on Tuesday, marking the best daily performance since July 23, 2025.
• 10 out of 12 analysts covering Abivax rate it a buy or strong buy, indicating broad analyst support.

§ 03 Strategic Context

• The upgrade follows previous concerns regarding cancer cases associated with initial trial data, indicating a significant turnaround in investor sentiment.
• The positive data and management's communication strategy play a crucial role in shaping market perceptions and supporting future funding and commercial efforts.

§ 04 Strategic Implications

• The immediate implication is a rise in Abivax's stock price and investor confidence, which may facilitate further investment or partnership opportunities.
• Long-term, the positive data could enhance the company's position in the biotech market, supporting a potential standalone product launch if commercial needs are met.

§ 05 Risks & Constraints

• There are ongoing risks regarding the cash runway necessary for continued operations and the path to market catalysts that could affect the company's financial stability.
• Competition in the biotech space and the need for a robust commercial strategy pose additional challenges to Abivax's growth trajectory.

§ 06 Watchlist / Forward Signals

• Upcoming milestones include further data releases and potential regulatory submissions that may influence stock performance and investor sentiment.
• Monitoring analyst ratings and market reactions to future clinical trial results will be essential to gauge the company's ongoing viability and growth potential.